STOCK TITAN
  1. Home
  2. News
  3. NXL

Nexalin Technology Inc - NXL STOCK NEWS

Welcome to our dedicated news page for Nexalin Technology (Ticker: NXL), a resource for investors and traders seeking the latest updates and insights on Nexalin Technology.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nexalin Technology's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nexalin Technology's position in the market.

News
Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
Rhea-AI Summary
Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) has regained compliance with Nasdaq's minimum bid price requirement under Nasdaq Rule 5550(a)(2). CEO Mark White expresses commitment to revolutionizing mental health treatment through neurostimulation technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.46%
Tags
none
-
News
Nexalin Technology CEO Provides Letter to Shareholders
Rhea-AI Summary
Nexalin Technology, Inc. (NXL) reports on growing clinical data supporting its neurostimulation technology and progress advancing its new Gen-3 HALO™ Clarity Virtual Clinic model. The company's CEO, Mark White, highlights positive clinical results, the introduction of HALO™ Clarity & Virtual Clinic, targeting the U.S. Government market, global market expansion, strengthening IP portfolio, and a bright future for Nexalin and mental health care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
none
-
News
Nexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing
Rhea-AI Summary
Nexalin Technology, Inc. completes successful testing for its new Gen-3 HALO™ Clarity neurostimulation device, ramping up manufacturing for upcoming clinical trials. The device offers remote treatment capabilities, potentially revolutionizing mental health disorder treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.72%
Tags
none
News
Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device
Rhea-AI Summary
Nexalin Technology, Inc. receives a new method of use patent for their non-invasive deep brain stimulation device, enabling treatment for anxiety, depression, and insomnia from the comfort of patients' homes. The patent covers the technology utilized in their Gen-3 HALO Clarity™ system, extending through 2040. CEO Mark White highlights the significance of the patent in enhancing the company's strategy and clinical data supporting the device's benefits. The Gen-3 system represents a state-of-the-art development in Nexalin's technology, offering painless neural stimulation for mental health conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.42%
Tags
none
-
News
Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board
Rhea-AI Summary
Nexalin Technology, Inc. appoints former Acting General Counsel to the Department of Veterans Affairs, William A. Hudson, Jr., to its Military & Government Advisory Board. Hudson's extensive experience in military and government law will aid Nexalin in advancing its non-invasive, deep-brain stimulation devices for mental health conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
51.05%
Tags
management
-
News
Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego
Rhea-AI Summary
Nexalin Technology, Inc. announced positive results from a clinical study on its Gen-2 tACS device for treating pain in veteran patients with Mild Traumatic Brain Injury (mTBI). The study showed a significant decrease in PCS and PTSD symptoms compared to the control group. The company's strategy aims to provide a non-medication treatment option for mTBI without side effects, supported by VA and UCSD collaboration. The study was a randomized, double-blind trial with promising outcomes, reinforcing Nexalin's commitment to improving mental healthcare outcomes for patients with mTBI.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
79.49%
Tags
clinical trial
News
Nexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment”
Rhea-AI Summary
Nexalin Technology, Inc. presented its Gen-3 Halo Clarity device at the 'State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment' hosted by USAMRDC and BARDA. The device aims to treat TBI, PTSD, and other conditions non-invasively. The company received positive feedback from leading experts and government officials, indicating a growing interest in non-drug therapeutic options for TBI.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.17%
Tags
none
-
News
Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia
Rhea-AI Summary
Nexalin Technology, Inc. announced positive results of a clinical study on its Gen-2 tACS device for chronic insomnia treatment. The study showed significant improvements in sleep parameters, with older participants benefiting more. Chronic insomnia affects 6-10% of adults worldwide, and the market for insomnia treatment is valued at over $5 billion. The study results were published in the Journal of Psychiatric Research, highlighting the device's efficacy and safety.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
49.55%
Tags
clinical trial
-
News
Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device
Rhea-AI Summary
Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) has received regulatory approval from the Sultanate of Oman’s Ministry of Health for its second generation neurostimulation device, marking the company's first regulatory approval outside of China. The CEO, Mark White, expressed excitement about entering the Middle East market and hinted at plans to seek approval in other international markets. The company aims to finalize a commercial distribution agreement in Oman and capitalize on the growing clinical data supporting the benefits of its non-invasive, drug-free device.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.02%
Tags
none
News
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System
Rhea-AI Summary
Nexalin Technology, Inc. announced the award of a U.S. patent for its non-invasive, frequency-based deep brain stimulation device, extending IP protection through 2040. The Gen-3 system is a significant advancement to the predecessor Gen-1 system, providing painless brain neural stimulation for mental health conditions. Clinical studies have demonstrated therapeutic benefits in conditions such as treatment-resistant depression, migraines, anxiety, and insomnia, with potential applications in addiction, substance use disorder, Alzheimer’s, traumatic brain injury, and PTSD. The global mental health market was estimated at $383 billion in 2020 and is projected to reach $537 billion by 2030, indicating significant market potential for Nexalin's neurostimulation device.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.89%
Tags
none
Stock NXL logo
Nexalin Technology Inc

Nasdaq:NXL

NXL Rankings

#5365 Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

NXL Stock Data

17.03M
5.89M
22.92%
0.65%
1.28%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States
Houston

About NXL

nexalin technology is a non-invasive and drug-free therapy for those living with anxiety, depression and/or insomnia. nexalin’s patented waveform (1 u.s. patent #6904322b2) the nexalin device produces a patented waveform that provides transcranial electrical stimulation (tes). in clinical trials, this unique waveform resulted in the greatest increase in beta-endorphins. the nexalin device has undergone extensive safety analysis with the results clearly indicating that the device is safe for its intended use. additionally, the fda classification of the device for clinical trials places it into a non-significant risk (low risk device) category. natural frequency will promote balance in the brain by normalizing neurochemistry.this effectiveness of this unique therapy is long lasting and fda approved. laboratory and clinical evidence suggest that nexalin’s patented electrical stimulation affects the hypothalamus and related brain structures to adapt and change the levels of neurochemicals